Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
518
NCT02329184
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 31, 2014
Completion: Apr 30, 2016
NCT02356289
Single Ascending Dose Study of MYK-461 in Healthy Volunteers
Start: Jan 31, 2015
Completion: Jul 31, 2015
NCT02480296
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers
Start: Aug 31, 2015
Completion: Oct 31, 2016
NCT02842242
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Phase: Phase 2
Start: Aug 31, 2016
Completion: Nov 30, 2017
NCT03062956
A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
Start: Jan 16, 2017
Completion: Nov 28, 2017
NCT03442764
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Start: Mar 30, 2018
Completion: Jan 7, 2020
NCT03470545
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Phase: Phase 3
Start: May 29, 2018
Completion: May 6, 2020